- Nucleoside reverse transcriptase inhibitors (NRTIs) may reduce the risk of developing Alzheimer's disease.
- The protective effect was consistent across different patient populations and remained significant after adjusting for potential biases.
- Inflammasome inhibition through NRTIs could benefit patients with Alzheimer's disease.
- The study provides epidemiologic support for the potential use of inflammasome inhibitors in AD.
- NRTIs such as lamivudine, emtricitabine, and K-9 are mentioned as potential candidates for future AD treatment.
Source: Alzheimer's and Dementia
